Bullous autoimmune dermatoses

2018 ◽  
Vol 16 (11) ◽  
pp. 1339-1358 ◽  
Author(s):  
Silke C. Hofmann ◽  
Hazem A. Juratli ◽  
Rüdiger Eming
Author(s):  
Ilona Hartmane ◽  
Iveta Ivdra ◽  
Ingmārs Mikažāns ◽  
Vanda Bondare-Ansberga

Abstract Psoriasis is one of the most common autoimmune dermatoses with a chronic relapsing course. Biologic therapy should be initiated for patients with moderate to severe psoriasis when conventional systemic therapy and phototherapy are ineffective, or their use is limited due to comorbidities. In Latvia, adalimumab is the first choice of biologic drugs for treatment of psoriasis. The correlation between changes in cellular and humoral immunological parameters and clinical signs based on immunological data from psoriasis patients are evaluated in the publication.


2022 ◽  
Vol 0 ◽  
pp. 1-8
Author(s):  
Abel Francis ◽  
Anjali Rose Jose

Immunosuppressive drugs are the main stay of treatment for autoimmune dermatoses. The main disadvantage of these drugs is the increased susceptibility to life-threatening infections. Hence, in recent years, there has been an enthusiastic search for newer groups of drugs that can reduce this risk. Immune enhancing agents are considered as the key players of future. Immune enhancers function by activating various elements of the immune system and thereby amplifying the immune responses. They can be specific or non-specific in action. The main autoimmune dermatoses where the benefits of these drugs have so far been utilized include alopecia areata, vitiligo, psoriasis, lichen planus, and discoid lupus erythematosus. Immunostimulants are available in both topical and systemic forms. Topical immune- enhancing agents include contact sensitizers (diphenylcyclopropenone, dinitrochlorobenzene, and squaric acid dibutyl ester), anthralin, topical zinc, and interferons. Systemic agents include levamisole, zinc, probiotics, and so on. The exact mechanism of action of some of these drugs and other autoimmune conditions where they can be benefited is not completely understood. Another therapeutic agent that may come up in the future is individualized vaccines. Let us look forward to the days when individualized vaccines work wonders in the management of autoimmune diseases.


2014 ◽  
pp. 21-29
Author(s):  
Mai P. Hoang ◽  
Maria Angelica Selim ◽  
Bruce Smoller

2004 ◽  
Vol 61 (5) ◽  
pp. 557-559 ◽  
Author(s):  
Milos Pavlovic ◽  
Rados Zecevic ◽  
Lidija Zolotarevski

Psoriasis has been consistently associated with arthritis and inflammatory bowel diseases, though there have been reports on patients with psoriasis and other autoimmune dermatoses. Sometimes, sharply demarcated scaly plaques located over extensor surfaces in patients with dermatomyositis may clinically resemble psoriatic lesions. Histologic findings of interface dermatitis, typical for dermatomyositis, help clinicians to rule out psoriasis. A patient is presented with dermatomyositis in which psoriatic lesions developed over the extremities and lower trunk. Histological examination confirmed the diagnosis of psoriasis. Both diseases have run independent courses. It is prudent to include psoriasis in the differential diagnosis of scaly eruptions occurring in dermatomyositis patients.


2021 ◽  
Vol 12 ◽  
Author(s):  
Stefan Tukaj ◽  
Jagoda Mantej ◽  
Michał Sobala ◽  
Katarzyna Potrykus ◽  
Zbigniew Tukaj ◽  
...  

Heat shock proteins (Hsp) are constitutive and stress-induced molecules which have been reported to impact innate and adaptive immune responses. Here, we evaluated the role of Hsp70 as a treatment target in the imiquimod-induced, psoriasis-like skin inflammation mouse model and related in vitro assays. We found that immunization of mice with Hsp70 resulted in decreased clinical and histological disease severity associated with expansion of T cells in favor of regulatory subtypes (CD4+FoxP3+/CD4+CD25+ cells). Similarly, anti-Hsp70 antibody treatment led to lowered disease activity associated with down-regulation of pro-inflammatory Th17 cells. A direct stimulating action of Hsp70 on regulatory T cells and its anti-proliferative effects on keratinocytes were confirmed in cell culture experiments. Our observations suggest that Hsp70 may be a promising therapeutic target in psoriasis and potentially other autoimmune dermatoses.


2016 ◽  
pp. 297-340
Author(s):  
Jie Zheng ◽  
Meng Pan ◽  
S. Gianfaldoni ◽  
A. M. D’Erme ◽  
T. Lotti ◽  
...  

2013 ◽  
Vol 53 (3) ◽  
pp. 294-299 ◽  
Author(s):  
Sarah Terras ◽  
Thilo Gambichler ◽  
Rose K. C. Moritz ◽  
Peter Altmeyer ◽  
Jo Lambert

2007 ◽  
Vol 300 (1) ◽  
pp. 3-9 ◽  
Author(s):  
Elizabeth Gaines ◽  
Victoria P. Werth

2020 ◽  
Vol 16 (1) ◽  
Author(s):  
Heng L. Tham ◽  
Keith E. Linder ◽  
Thierry Olivry

AbstractPemphigus is the term used to describe a group of rare mucocutaneous autoimmune bullous diseases characterized by flaccid blisters and erosions of the mucous membranes and/or skin. When the autoantibodies target desmosomes in the deep layers of the epidermis, deep pemphigus variants such as pemphigus vulgaris, pemphigus vegetans and paraneoplastic pemphigus develop. In this article, we will review the signalment, clinical signs, histopathology and treatment outcome of pemphigus vulgaris, pemphigus vegetans and paraneoplastic pemphigus in dogs, cats and horses; where pertinent, we compare the animal diseases to their human homologue. Canine, feline and equine pemphigus vulgaris, pemphigus vegetans and paraneoplastic pemphigus have many features similar to the human counterpart. These chronic and often relapsing autoimmune dermatoses require aggressive immunosuppressive therapy. In animals, the partial-to-complete remission of pemphigus vulgaris and pemphigus vegetans has been achieved with high dose glucocorticoid therapy, with or without adjunct immunosuppressants; the prognosis is grave for paraneoplastic pemphigus.


Sign in / Sign up

Export Citation Format

Share Document